Immedica starts to distribute Ravicti<sup>®</sup> and Ammonaps<sup>®</sup> in Europe and the Middle East from 1 January 2020


In December 2018, Immedica acquired the rights for the products Ammonaps® (Sodium phenylbutyrate) and Ravicti® (Glycerol phenylbutyrate), from Horizon Therapeutics in all territories outside North America and Japan. On June 6, 2019, Immedica became the Market Authorization Holder (MAH) for Ammonaps® and Ravicti®, in 28 EU member countries, Norway and Iceland. As a next step […]